Galapagos NV 2024 AR2
The report highlights Galapagos' strategic transformation in 2024, focusing on its decentralized cell therapy manufacturing platform and oncology pipeline. Key achievements include FDA clearance for the Phase 1/2 ATALANTA-1 study of its lead CD19 CAR-T candidate, GLPG5101, and the successful transfer of the Jyseleca business to Alfasigma. Financially, the company reported total net revenues of ‒275.6 million from continuing operations and maintained a strong cash position of ‒3.3 billion. Additionally, Galapagos announced plans to separate into two publicly traded entities by mid-2025 to unlock shareholder value and sharpen its oncology focus.
Company: Galapagos NV
Sector: Health Care
Country: Belgium
Year: 2024
Type: AR2
Pages: 256
Galapagos NV
Annual Report
The report highlights Galapagos' strategic transformation in 2024, focusing on its decentralized cell therapy manufacturing platform and oncology pipeline. Key achievements include FDA clearance for the Phase 1/2 ATALANTA-1 study of its lead CD19 CAR-T candidate, GLPG5101, and the successful transfer of the Jyseleca business to Alfasigma. Financially, the company reported total net revenues of ‒275.6 million from continuing operations and maintained a strong cash position of ‒3.3 billion. Additionally, Galapagos announced plans to separate into two publicly traded entities by mid-2025 to unlock shareholder value and sharpen its oncology focus.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Women on Board
Net Zero Target
Employees